Taking drugs of any kind is never without risks, but setbacks surrounding the vigorously marketed COX-2 inhibitors have really brought this home.
It's been tough going for pain relievers since the pharmaceutical company Merck pulled its COX-2 inhibitor rofecoxib (Vioxx) from the market in fall 2004, valdecoxib (Bextra) was pulled in March 2005, and the one remaining COX-inhibitor, celecoxib (Celebrex), was also found to have cardiovascular risks.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.